-
1.发明申请公开(公告)号：US20200271601A1
公开(公告)日：2020-08-27
申请号：US16824895
申请日：2020-03-20
摘要： A nuclear magnetic resonance method of analysis for glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, is provided. The method allows for their identification and for relative quantification of respective characteristic signals by 1H-NMR and/or 1H-13C HSQC.
-
公开(公告)号：US11987410B2
公开(公告)日：2024-05-21
申请号：US17235012
申请日：2021-04-20
摘要： A sterile procedure for the filing of solids into pharmaceutical containers and the sealing thereof under sterile conditions is provided. Exemplary containers include syringes, vials, capsules, ampoules, single-dose devices or cartridges. The containers can be filled with powder, granules, nanoparticles or microparticles. After sealing, the containers are airtight. More specifically, the procedure minimizes adherence of those solids to the interior surfaces of the containers during the filling and sealing steps, thus ensuring airtightness of the seal and precision of the weight of the solid dispensed into the containers.
-
3.发明授权公开(公告)号：US11827391B2
公开(公告)日：2023-11-28
申请号：US16585248
申请日：2019-09-27
IPC分类号： B65B1/32 , A61J3/07 , A61K31/4196 , A61K31/519 , B65B1/04 , G01G15/00 , B65B1/06 , A61J1/00
CPC分类号： B65B1/32 , A61J3/07 , A61K31/4196 , A61K31/519 , B65B1/04 , B65B1/06 , G01G15/00 , A61J1/00
摘要： A system for and method of gravimetric filling of a solid product in sterile conditions in a pharmaceutical container of small dimensions including syringes, vials, capsules, ampoules, single-dose devices, inhalers, bottles, carpules, well(s) of blister pack(s), sachets or bags with solid substances selected from the group formed by powder, lyophilizate, granules, pellets, nanoparticles or microparticles. More particularly, it relates to a process for the gravimetric filling of pharmaceutical containers with one or more sterile solid pharmaceutical substances or sterile excipients dosed and prepared in an aseptic environment.
-
公开(公告)号：US20210154302A1
公开(公告)日：2021-05-27
申请号：US17101585
申请日：2020-11-23
IPC分类号： A61K47/34 , A61L2/00 , A61K31/426 , A61K9/00
摘要： An injectable depot composition suitable for forming an in situ intramuscular implant is provided. The composition includes sterile biodegradable thermoplastic polymer of polylactic acid (PLA), solvent for the PLA, and drug. After administration to a subject, a corresponding implant administers 0.1-2 milligrams of nonsteroidal aromatase inhibitor every day throughout a dosing period of about six months to about one year. The composition is used to treat subjects in need thereof.
-
公开(公告)号：US20190321286A1
公开(公告)日：2019-10-24
申请号：US16456900
申请日：2019-06-28
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
摘要： The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
-
公开(公告)号：US20150150791A1
公开(公告)日：2015-06-04
申请号：US14555287
申请日：2014-11-26
IPC分类号： A61K9/00 , A61K47/20 , A61K9/14 , A61K31/519 , A61K47/34
CPC分类号： A61K9/0024 , A61K31/519 , A61K47/34
摘要： The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
摘要翻译： 本发明涉及一种适用于在体内形成原位固体植入物的可注射肌内贮存组合物，其包含任意组合的利培酮和/或普利培酮或其任何药学上可接受的盐的药物，基于乳酸的生物相容性共聚物和 具有约50:50的乳酸与乙醇酸的单体比率的乙醇酸和DMSO溶剂，其中所述组合物立即起始作用释放药物并连续至少4周，并且其中所述组合物在体内具有药代动力学特征 这使得它适合于每4周或更长时间施用。
-
公开(公告)号：US11918682B2
公开(公告)日：2024-03-05
申请号：US17172771
申请日：2021-02-10
IPC分类号： A61K9/00 , A61K31/4196 , A61K47/34
CPC分类号： A61K9/0024 , A61K31/4196 , A61K47/34
摘要： The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.
-
公开(公告)号：US20210316890A1
公开(公告)日：2021-10-14
申请号：US17235012
申请日：2021-04-20
摘要： A sterile procedure for the filing of solids into pharmaceutical containers and the sealing thereof under sterile conditions is provided. Exemplary containers include syringes, vials, capsules, ampoules, single-dose devices or cartridges. The containers can be filled with powder, granules, nanoparticles or microparticles. After sealing, the containers are airtight. More specifically, the procedure minimizes adherence of those solids to the interior surfaces of the containers during the filling and sealing steps, thus ensuring airtightness of the seal and precision of the weight of the solid dispensed into the containers.
-
公开(公告)号：US11013683B2
公开(公告)日：2021-05-25
申请号：US16429333
申请日：2019-06-03
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
摘要： An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.
-
公开(公告)号：US08802156B2
公开(公告)日：2014-08-12
申请号：US13193977
申请日：2011-07-29
CPC分类号： A61K9/2027 , A61K9/2072
摘要： A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.
摘要翻译： 含有硫酸化糖胺聚糖药物和聚阳离子聚合物或共聚物的药物组合物，其中药物组合物中铵基团的比例为0.01-2.0μmol/ mg药物组合物，药物形式中糖胺聚糖的比例为15％至 50％w / w，药物组合物的含水量为10重量％以下。 含有药物组合物的药物剂型及其用于治疗对糖胺聚糖治疗反应的疾病或病症的用途。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.021 秒)
